About clonoSEQ

A test that’s as mighty as today’s cancer treatments

clonoSEQ is a blood or bone marrow test1 that measures your cancer at the deepest level currently available,1-3 helping your doctor make more informed decisions about your care. It is CLIA-validated in bone marrow and peripheral blood for diffuse large B-cell lymphoma (DLBCL).

clonoSEQ is a blood or bone marrow test1 that measures your cancer at the deepest level currently available,1-3 helping your doctor make more informed decisions about your care. It is CLIA-validated in bone marrow and peripheral blood for diffuse large B-cell lymphoma (DLBCL).

clonoSEQ helps your doctor tailor treatment to your needs

clonoSEQ uses next-generation sequencing technology, an advanced testing method that decodes your cancer’s genetic information, to look for unique cancer DNA sequences that serve as “barcodes.” After your diagnosis, clonoSEQ identifies and counts your cancer’s unique “barcodes.” During treatment and remission, clonoSEQ can tell you and your doctor if and how the number of “barcodes” has changed since your last MRD test.1

clonoSEQ is covered by Medicare and other major insurance providers

“If there was one word to describe receiving my MRD results, I would say, hope.”

— Tiffany, a blood cancer patient who had clonoSEQ testing

clonoSEQ provides the most sensitive measurement of MRD currently available1-3

When it comes to cancer, knowledge is power. By precisely tracking MRD both during and after treatment, you and your doctor can be more informed about your response to therapy—and can plan next steps accordingly.1

clonoSEQ can identify residual disease that other tests miss

While traditional tests used in DLBCL, such as PET/CT imaging, can help your doctor get a big-picture view of your cancer, they can’t always detect low levels of disease and may even provide inaccurate or incomplete results. Imaging predicts cancer recurrence accurately less than 60% of the time, highlighting the need for other forms of testing.4-7

When used to measure MRD in DLBCL patients after their first treatment, clonoSEQ was shown to detect signs of cancer recurrence a median of

3.5 months before relapse8

clonoSEQ can help clarify imaging results, so you and your doctor can take action earlier

Measure, then treat. Treat, then measure.
Repeat throughout your journey.

There can be several stages of treatment for DLBCL. Your doctor may want to monitor your MRD status at various points to track your progress. Your MRD test results with clonoSEQ may guide the choice of which treatment comes next.

Click through to see when your doctor may test you with clonoSEQ.

(1 of 4)

Initial diagnosis1

Identify cancer cell DNA
(Clonality (ID) Test)
The clonoSEQ Clonality (ID) Test provides a baseline. Because this test is done on the largest number of cancer cells, it helps clonoSEQ know which cells to track over time in subsequent MRD tests.

(2 of 4)

During first-line treatment9,10

The most common first treatment for DLBCL is a combination chemotherapy called R⁠-⁠CHOP. Your doctor may want to monitor your progress both during and right after treatment to see how it’s working. You’ll likely get PET/CT scans, but your doctor may also recommend MRD testing with clonoSEQ.

(3 of 4)

During surveillance9,10

If you’re in remission and off treatment, your doctor will still likely keep track of your DLBCL for 2 years or more. During this time, MRD testing with clonoSEQ may be helpful to detect any relapse as early as possible. That will help you plan for potential later-line treatments.

(4 of 4)

During later-line treatments9,11,12

If you need more treatment, there are a few options. You may get more chemotherapy or immunotherapy, stem cell transplant, or a newer option called CAR T-cell therapy (or a mix of more than one of these). Whatever course you take, MRD testing with clonoSEQ can help track how well treatment is working and inform next steps.

Talk to your doctor about clonoSEQ

Here are some questions to help you start a conversation with your doctor.

  • Is MRD testing with clonoSEQ right for me?
  • I heard that clonoSEQ is the most sensitive MRD test available. Why does that matter for me?
  • What can MRD testing with clonoSEQ tell me about my cancer?
  • How will you incorporate MRD results from clonoSEQ into my treatment plan?
  • At what points during the treatment process should I have a clonoSEQ MRD test?

Be sure to check in with your doctor regularly. This way, you can ensure you are on track with the MRD goals you’ve set together.

Take a look at a sample clonoSEQ report

Sample clonoSEQ Report

This page is intended for a US-based audience.

clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect measurable residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). Additionally, clonoSEQ is available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). To review the FDA-cleared uses of clonoSEQ, visit clonoSEQ.com/technical-summary.

References:

  1. clonoSEQ®. [technical summary]. Seattle, WA: Adaptive Biotechnologies; 2020.
  2. Short NJ, et al. Am J Hematol. 2019;94:257-265.
  3. Martinez-Lopez J, et al. J Hematol Oncol. 2021;14(1):126.
  4. Suh K, et al. Korean J Intern Med. 2019;34(4):894-901.
  5. Carr R, et al. J Nucl Med. 2014;55(12):1936-1944.
  6. Mamot C, et al. J Clin Oncol. 2015;33(23):2523-2529.
  7. Thompson C, et al. J Clin Oncol. 2014;32(31):3506-3512.
  8. Roschewski M, et al. Lancet Oncol. 2015;16(5):541-549.
  1. Referenced with permission from the NCCN Guidelines for Patients®️ for Diffuse Large B-Cell Lymphomas, 2022. ©️National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed January 16, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  2. Hu R, et al. Curr Oncol Rep. 2019;21(5):44.
  3. Merryman R, et al. Paper presented at: 65th ASH Annual Meeting and Exposition; December 5-8, 2020 [virtual]. Abstract 531.
  4. Frank M, et al. J Clin Oncol. 2021;39(27):3034-3043.